Aclarion (NASDAQ:ACON – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.
Aclarion Stock Performance
Shares of ACON opened at $6.40 on Friday. The company’s fifty day moving average is $8.34 and its 200-day moving average is $414.77. Aclarion has a 12 month low of $6.20 and a 12 month high of $3,499.51.
Aclarion (NASDAQ:ACON – Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($9.32) EPS for the quarter, topping the consensus estimate of ($1,447.20) by $1,437.88. Aclarion had a negative net margin of 12,845.05% and a negative return on equity of 422.87%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Analysts expect that Aclarion will post -263.33 EPS for the current year.
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Read More
- Five stocks we like better than Aclarion
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- ESG Stocks, What Investors Should Know
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- Breakout Stocks: What They Are and How to Identify Them
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
